The South Eastern Chapter of the American Association of Physicists in Medicine (SEAAPM) has chosen Immunolight’s paper, X-Ray Psoralen Activated Cancer Therapy to receive it’s 2017’s best paper award.
We are excited and honored to announce that Crain’s Detroit Business News has named Immunolight LLC as the most innovative company in Detroit for 2016. The award is the result of an independent annual survey called the Eureka Index that scores companies on READ MORE
In collaboration with the NC State College of Veterinary Medicine, Immunolight therapy for canine cancer is now recruiting potential candidates for our Phase II Study. After a successful Phase I Safety Study, the goal of this new research project is to continue studying and refining Immunolight Therapy, an innovative approach to cancer treatment.
Over the past 18 months, the team at Immunolight, along with physicians, veterinarians, scientists and support personnel from the departments of Radiation Oncology at NCSU’s College of Veterinary Medicine and Duke University’s Medical Center, have been conducting a groundbreaking canine pilot study to develop and test Immunolight therapy in the ongoing battle against cancer.
Immunolight LLC, an emerging leader in the development of a breakthrough platform technology leveraging the latest advances in energy transfer, has announced research about a new mode of action utilizing psoralen, a naturally occurring compound found in broccoli and figs, that may shed new light on the fight against cancer.